LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be
Month: September 2026
AUSTIN, Texas, Sept. 25, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the fiscal year ended June 30, 2026.
Financial Highlights & Fiscal Year Developments
- As of June 30, 2026, the Company had deployed the TRACER 1000 in approximately 37 locations in 16 countries across the United States, Europe and Asia.
- The Company launched its Labrador ruggedized Handheld Gas Chromatograph designed to bring laboratory-grade volatile organic compound analysis directly to the point of investigation.
- The Board of Directors of the Company approved a strategic initiative focused on potential future lunar resource development, autonomous lunar industrial infrastructure, Moon based advanced computing, semiconductor, manufacturing, lunar power generation and power infrastructure, mining, chemical manufacturing, product transportation and equipment leasing opportunities on the Moon through its newly formed subsidiary, Lunar Power and Light Corporation. As part of the initiative, Astrotech intends to evaluate and potentially develop infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface.
- Total operating expenses were $14 million, a decline of 6% during the fiscal year ended June 30, 2026, compared to the fiscal year ended June 30, 2025.
- Astrotech’s consolidated balance sheet consisted of $11.3 million in cash and cash equivalents and short-term investments as of June 30, 2026, which the Company believes will support operating expenses and capital expenditure requirements.
“Our fiscal year 2026 results reflect an important period of investment and progress. We have advanced several priorities that strengthen the foundation for scalable growth, including the launch of our new lunar resource and infrastructure strategic initiatives. We believe these initiatives could expand our addressable opportunities and position us to better serve customers over the long term. We enter the new year focused on executing on these opportunities with the goal of converting pipeline opportunities into revenue growth,” stated Thomas B. Pickens, III, Astrotech’s Chairman, Chief Executive Officer and Chief Technology Officer.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:
- 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening applications.
- AgLAB designs process analyzers tailored to the agriculture industry.
- Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
- EN-SCAN, Inc. delivers portable, ruggedized environmental testing solutions that integrate gas chromatography and mass spectrometry for use in challenging field environments.
- Lunar Power and Light focused on potentially developing infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface.
Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com
Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, the Company’s lunar infrastructure initiatives, potential NASA selection, funding, awards or contracts, technology development, partnerships, autonomous systems, lunar resource mining and processing, advanced manufacturing, power development, artificial intelligence, quantum computing, advanced semiconductor materials and commercial lunar activity, future engineering and testing, technology qualification, commercialization and potential lunar resource deployment and long-duration energy storage; and the Company’s ability to finance, validate, launch, operate or commercialize related systems, and the potential effects of the addition of advisors, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements in this document should be evaluated in light of these important risk factors. The contemplated lunar energy-storage application remains in the evaluation and development stage. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Company Contact:
Scott Bartley
Interim Chief Financial Officer, Astrotech Corporation
(512) 485-9530
Tables follow
| ASTROTECH CORPORATION Consolidated Statements of Operations and Other Comprehensive Loss (In thousands, except per share data) |
||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 913 | $ | 1,049 | ||||
| Cost of revenue | 696 | 574 | ||||||
| Gross profit | 217 | 475 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | 7,871 | 7,067 | ||||||
| Research and development | 6,484 | 8,142 | ||||||
| Total operating expenses | 14,355 | 15,209 | ||||||
| Loss from operations | (14,138 | ) | (14,734 | ) | ||||
| Interest and dividend income | 471 | 1094 | ||||||
| Realized loss | (543 | ) | (5 | ) | ||||
| Other income and expense, net | (213 | ) | (203 | ) | ||||
| Total other income(expense) | (285 | ) | 886 | |||||
| Loss from operations before income taxes | (14,423 | ) | (13,848 | ) | ||||
| Income tax benefit /(expense) | (4 | ) | (2 | ) | ||||
| Net loss | $ | (14,427 | ) | $ | (13,850 | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and diluted | 1,700 | 1,665 | ||||||
| Basic and diluted net loss per common share: | ||||||||
| Net loss per common share | $ | (8.49 | ) | $ | (8.32 | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Net loss | $ | (14,427 | ) | $ | (13,850 | ) | ||
| Available-for-sale securities: | ||||||||
| Net unrealized gain | 548 | 313 | ||||||
| Total comprehensive loss | $ | (13,879 | ) | $ | (13,537 | ) | ||
| ASTROTECH CORPORATION Consolidated Balance Sheets (In thousands, except share and per share data) |
||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 8,387 | $ | 3,100 | ||||
| Short-term investments | 2,947 | 15,108 | ||||||
| Accounts receivable | 124 | 485 | ||||||
| Inventory, net: | ||||||||
| Raw materials | 2,926 | 2,194 | ||||||
| Work-in-process | 9 | 425 | ||||||
| Finished goods | 1,179 | 310 | ||||||
| Prepaid expenses and other current assets | 354 | 353 | ||||||
| Total current assets | 15,926 | 21,975 | ||||||
| Property and equipment, net | 2,383 | 2,395 | ||||||
| Intangible assets, net | 50 | 48 | ||||||
| Operating lease right-of-use assets, net | 1,834 | 2,225 | ||||||
| Other assets, net | 314 | 346 | ||||||
| Total assets | $ | 20,507 | $ | 26,989 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 581 | $ | 1,066 | ||||
| Payroll related accruals | 482 | 529 | ||||||
| Accrued expenses and other liabilities | 912 | 451 | ||||||
| Lease liabilities, current | 282 | 405 | ||||||
| Total current liabilities | 2,257 | 2,451 | ||||||
| Accrued expenses and other liabilities, net of current portion | 54 | 164 | ||||||
| Lease liabilities, net of current portion | 2,024 | 2,274 | ||||||
| Total liabilities | 4,335 | 4,889 | ||||||
| Commitments and contingencies (Note 14) | ||||||||
| Stockholders’ equity | ||||||||
| Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at June 30, 2026 and 2025, respectively | — | — | ||||||
| Common stock, $0.001 par value, 250,000,000 shares authorized at June 30, 2026 and 2025 respectively; 2,009,050 and 1,769,269 shares issued at June 30, 2026 and 2025 respectively; 1,998,734 and 1,758,953 outstanding at June 30, 2026 and 2025, respectively | 190,643 | 190,643 | ||||||
| Treasury shares, 10,316 shares at June 30, 2026 and 2025, respectively | (119 | ) | (119 | ) | ||||
| Additional paid-in capital | 91,261 | 83,310 | ||||||
| Accumulated deficit | (265,297 | ) | (250,870 | ) | ||||
| Accumulated other comprehensive loss | (316 | ) | (864 | ) | ||||
| Total stockholders’ equity | 16,172 | 22,100 | ||||||
| Total liabilities and stockholders’ equity | $ | 20,507 | $ | 26,989 | ||||
Originally published on CVS Health Company Newsroom
The demand for reliable energy continues to grow, and for CVS Health, dependable operations are essential to serving millions of patients and customers across the country. That’s why we’re expanding our use of renewable electricity and investing in energy solutions that help reduce emissions, strengthen business resilience and support uninterrupted care. These efforts are part of our goal to source 50% of our energy from renewable electricity by 2040 while building a healthier, more sustainable future for the communities we serve.
Through new and expanded power purchase agreements (PPAs), we’re increasing our use of clean electricity to support our operations. These efforts are part of our broader approach to sustainability, one that’s rooted in improving health outcomes over time.
“As a health solutions company, we recognize that the health of our communities is closely connected to the health of our environment,” said Jenny McColloch, Chief Sustainability Officer of CVS Health. “By investing in renewable energy, we’re reducing emissions, strengthening the resilience of our operations and ensuring continuity of care for the patients and customers we serve in communities across the country.”
Why renewable energy agreements matter
The need for reliable, affordable energy is growing, especially as industries expand and power demand increases. Across sectors, organizations are turning to renewable energy sources to strengthen long-term energy stability and manage costs.
For CVS Health, renewable energy agreements help support the stores, pharmacies, clinics and facilities that patients and customers rely on every day. They also help strengthen the energy system and support a cleaner future for the communities we serve.
What’s happening
Since 2022, we’ve made seven large-scale investments in renewable energy. Most recently in Maryland and putting energy-saving solutions into practice across our operations to reduce energy use and improve efficiency.
So far, we’ve secured agreements to source more than 969,000 megawatt hours (MWh) of clean energy as these projects come online. These efforts are helping move us closer to our goal of sourcing 50% renewable electricity by 2040. In 2025, renewable electricity represented approximately 33% of our total electricity use.
How a renewable energy power purchase agreement works
A power purchase agreement is a long-term contract that supports the development of renewable energy projects, such as solar and wind farms, while allowing CVS Health to purchase renewable electricity without building or operating the projects ourselves.
Here’s how it works in practice:
- Renewable energy is generated offsite from projects across the U.S.
- That energy is delivered to the grid and helps increase the overall supply of clean electricity
- CVS Health receives the environmental benefits, which are credited against our electricity use
These agreements typically span multiple years, providing predictable access to clean energy sources while supporting the development of new renewable capacity.
What clean energy means for CVS Health’s carbon footprint
Our renewable energy investments are a key part of reducing our Scope 2 GHG emissions – the emissions associated with the electricity we use to operate our stores, clinics and facilities.
By increasing the amount of clean electricity in our energy mix, we’re making steady progress toward lowering our overall carbon footprint.
These efforts help us:
- Improve the efficiency of how we operate
- Support long-term energy reliability
- Contribute to a more sustainable energy system
All of which ultimately support the communities and patients we serve. They also help improve air quality by reducing reliance on fossil fuels, which can contribute to respiratory and cardiovascular health issues. At the same time, investing in a more resilient energy system helps us continue serving patients and communities during periods of increased demand and extreme weather.
The bottom line
Investing in renewable energy is one way we’re helping build a healthier future. By reducing emissions, supporting cleaner air and strengthening the resilience of our operations, we’re helping ensure we can continue caring for patients and serving communities today and in the years ahead.
ATLANTA–(BUSINESS WIRE)–QumulusAI (Nasdaq: QMLS), a neocloud infrastructure provider purpose-built for the AI computing era, today announced the release of a new Futurum Research report, sponsored by QumulusAI, which finds that agentic AI can increase token consumption per task by 10 to 100 times compared with a simple inference call. That increase can expose organizations using per-token services to unpredictable and rising costs as applications move into production and scale across the enter
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on September 29, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 25 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plans.
The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X700. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 1,013,515. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the reverse stock split, CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
TEL AVIV, ISRAEL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Arbe Robotics Ltd. (NASDAQ: ARBE), (TASE: ARBE) (“Arbe” or the “Company”), a global leader in ultra-high-resolution radar solutions, today announced that it has priced an underwritten registered direct offering of 833,334 ordinary shares at a purchase price of $0.60 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 24,166,666 ordinary shares at a purchase price of $0.5999 per share, which equals the offering price per ordinary share less the $0.0001 exercise price per share of each pre-funded warrant. The pre-funded warrants are immediately exercisable and will not expire until exercised in full. All ordinary shares and pre-funded warrants to be sold in the offering will be offered by the Company.
Arbe estimates the gross proceeds from this offering to be approximately $15 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 28, 2026, subject to the satisfaction of customary closing conditions. Arbe intends to use the net proceeds from this offering for working capital and general corporate purposes, including, but not limited to, scaling its operations to support growing commercial opportunities, including the recently announced selection of Arbe’s radar technology for an L3 passenger vehicle program of one of the world’s largest automotive groups and its intended expansion into the defense and counter-drone markets, as well as to potentially pursue potential strategic merger and acquisition opportunities.
Canaccord Genuity is acting as sole bookrunner for the offering.
The securities described above are being offered pursuant to a registration statement on Form F-3 (File No. 333-287805), originally filed on June 5, 2025, with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on June 13, 2025. The offering is being made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained, when available, by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Arbe Robotics Ltd.
Arbe (NASDAQ: ARBE), a global leader in ultra-high-resolution radar solutions, is redefining radar as a core sensing platform for next-generation mobility and defense. Arbe’s complete radar technology stack, from proprietary chipsets to radar systems and AI algorithms that produce perception-ready data, delivers the detail and real-time processing that demanding sensing applications require. Arbe enables OEMs, Tier-1s, and defense integrators to build more capable perception systems for passenger vehicles, robotaxis, heavy machinery, and counter-drone systems.
Headquartered in Tel Aviv, Israel, Arbe also operates offices in the United States, Germany, and China. For more information, visit https://arberobotics.com/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected timing, completion or size of the offering, the expected gross proceeds therefrom, and the intended use of net proceeds therefrom. The words “expect,” “believe,” “estimate,” “intend,” “plan,” “anticipate,” “may,” “should,” “strategy,” “future,” “will,” “project,” “potential” and similar expressions indicate forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These risks and uncertainties include the possible delisting of the Company’s ordinary shares from Nasdaq in the event the bid price per share of the Company’s ordinary shares remains below $1.00, the effect on the Israeli economy generally and on the Company’s business resulting from the terrorism and the hostilities in Israel, including the continuing hostilities with Iran, Hezbollah and Hamas and any intensification of hostilities, and the effect of the call-up of a significant portion of its working population, including the Company’s employees, the ability of the Company to develop and market the Alerion radar system and deliver units in a timely and profitable manner, the ability of the Alerion radar system to operate as planned under wartime conditions, and the risks and uncertainties described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” and in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2026, as well as other documents filed by the Company with the SEC. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation. Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.
Investor Relations:
Ehud Helft & Kenny Green
EK Global Investor Relations
+1 212 378 8040
In 2017, I was a young student nurse in Kenya, grappling with the stark realities of our national healthcare system. I saw families drained financially and emotionally by long-term hospital stays for their loved ones. The pain was not just in the illness but in the struggle for dignity and care. This is where Bena Care began—from a deep conviction that healthcare could be more compassionate, more accessible.
A perspective by Naom Monari, Founder & Chief Executive Officer, Bena Care
Bena Care builds a network of healthcare workers, primarily made up of nurses, physiotherapists and caregivers to deliver affordable home-nursing services and in-home therapy for chronically ill patients. Today, Bena Care has served over 16,000 patients, bringing care into homes where it’s needed most. Many of them report that this service has the potential to save them up to half of their healthcare costs. But behind these numbers are stories—a mother relieved that her son can receive dialysis closer to home, a daughter able to provide care for her mother because she was trained by our team. These are the stories that keep me going, even when the road ahead looks incredibly difficult to navigate.
- Bena Care has served over 16,000 patients, bringing care into homes where it’s needed most.
A lifeline in Boehringer Ingelheim: expanding health coverage options
In 2021, Bena Care reached a critical juncture. Running a social enterprise in healthcare is not for the faint-hearted. The financial pressures, the systemic challenges, the endless need—it can feel insurmountable. That’s when Boehringer Ingelheim’s Making More Health (MMH) entrepreneur support program came into our lives. It was more than just an opportunity, it was validation. Someone saw the potential in what we were doing and said: “Let’s make this bigger.”
Through MMH, we piloted programs that had long been part of my vision. We trained family caregivers, empowering them to provide supportive care. We launched free screenings in communities heavily burdened by diabetes and hypertension, focusing on early detection and intervention. These initiatives didn’t just work—they transformed us. Even after the program ended, these programs remained at the heart of Bena Care’s mission.
Read the whole piece on Imagine – Boehringer Ingelheim’s sustainability story hub.
In accordance with section 30 of the Capital Markets Act, Tryg A/S (“Tryg”) hereby announces that BlackRock, Inc. has notified Tryg that BlackRock, Inc. holds shares and voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, corresponding to more than 5% of the entire share capital and voting rights of Tryg. Please see further details in the attached notification form.
Additional information
Contact information:
- Gianandrea Roberti, Head of Financial Reporting, SVP, +45 20 18 82 67, gianandrea.roberti@tryg.dk
- Robin Hjelgaard Løfgren, Head of Investor Relations, +45 41 86 25 88, robin.loefgren@tryg.dk
Attachment
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% – January 24.09.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,440,016.04 29.600
LEOBENDORF, Austria–(BUSINESS WIRE)– #aestheticmedicine–Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company’s saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and ev